- Language: English
- Published: November 2012
Pharmaceuticals in Belgium
- ID: 2064138
- April 2014
- Region: Belgium
- 34 pages
Pharmaceuticals in Belgium industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2009-13, and forecast to 2018). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Belgium pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
- The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). Any currency conversions used in the production of this report have been calculated at constant 2013 annual average exchange rates.
- The Belgian pharmaceuticals market had total revenues of $5.7bn in 2013, representing a compound annual rate of change (CARC) of -0.2% between 2009 and 2013.
- The performance of the market is forecast to accelerate, with an anticipated compound annual growth rate (CAGR) of 2.7% for the five-year period 2013 - 2018, which is expected to drive the market to a value of $6.5bn by the end of 2018.
Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Belgium
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Belgium
Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Belgium pharmaceuticals market with five year forecasts
Macroeconomic indicators provide insight into general trends within the Belgium economy
Key Questions Answered
What was the size of the Belgium pharmaceuticals market by value in 2013?
What will be the size of the Belgium pharmaceuticals market in 2018?
What factors are affecting the strength of competition in the Belgium pharmaceuticals market?
How has the market performed over the last five years?
Who are the top competitiors in Belgium's pharmaceuticals market? SHOW LESS READ MORE >
Market value forecast
Market value forecast
Five Forces Analysis
Threat of substitutes
Degree of rivalry
Related MarketLine research
LIST OF TABLES
Table 1: Belgium pharmaceuticals market value: $ billion, 2009–13
Table 2: Belgium pharmaceuticals market geography segmentation: $ billion, 2013
Table 3: Belgium pharmaceuticals market share: % share, by value, 2013
Table 4: Belgium pharmaceuticals market value forecast: $ billion, 2013–18
Table 5: AstraZeneca PLC: key facts
Table 6: AstraZeneca PLC: key financials ($)
Table 7: AstraZeneca PLC: key financial ratios
Table 8: GlaxoSmithKline Plc: key facts
Table 9: GlaxoSmithKline Plc: key financials ($)
Table 10: GlaxoSmithKline Plc: key financials (£)
Table 11: GlaxoSmithKline Plc: key financial ratios
Table 12: Pfizer Inc.: key facts
Table 13: Pfizer Inc.: key financials ($)
Table 14: Pfizer Inc.: key financial ratios
Table 15: Belgium size of population (million), 2009–13
Table 16: Belgium gdp (constant 2000 prices, $ billion), 2009–13
Table 17: Belgium gdp (current prices, $ billion), 2009–13
Table 18: Belgium inflation, 2009–13
Table 19: Belgium consumer price index (absolute), 2009–13
Table 20: Belgium exchange rate, 2009–13
LIST OF FIGURES
Figure 1: Belgium pharmaceuticals market value: $ billion, 2009–13
Figure 2: Belgium pharmaceuticals market geography segmentation: % share, by value, 2013
Figure 3: Belgium pharmaceuticals market share: % share, by value, 2013
Figure 4: Belgium pharmaceuticals market value forecast: $ billion, 2013–18
Figure 5: Forces driving competition in the pharmaceuticals market in Belgium, 2013
Figure 6: Drivers of buyer power in the pharmaceuticals market in Belgium, 2013
Figure 7: Drivers of supplier power in the pharmaceuticals market in Belgium, 2013
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Belgium, 2013
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Belgium, 2013
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Belgium, 2013
Figure 11: AstraZeneca PLC: revenues & profitability
Figure 12: AstraZeneca PLC: assets & liabilities
Figure 13: GlaxoSmithKline Plc: revenues & profitability
Figure 14: GlaxoSmithKline Plc: assets & liabilities
Figure 15: Pfizer Inc.: revenues & profitability
Figure 16: Pfizer Inc.: assets & liabilities